Literature summary for 3.4.22.56 extracted from

Schrieber, S.J.; Wen, Z.; Vourvahis, M.; Smith, P.C.; Fried, M.W.; Kashuba, A.D.; Hawke, R.L.
The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3/7 activity (2008), Drug Metab. Dispos., 36, 1909-1916.

Search for more literature for 3.4.22.56

Application

Application	Comment	Organism
diagnostics	a simple biochemical assay of caspase-3 activity in blood, may be useful for predicting the disposition of drugs that undergo extensive conjugation and biliary elimination like silymarin in patients with liver disease, caspase-3 activity correlates with the amount of silymarin conjugates, e.g. silychristin and silybin A and B, and is 5fold higher in the HCV cirrhosis cohort, overview	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
liver	the caspase-3 activity is about 2.4, 3.3, and 4.7fold higher in hepatitis C virus noncirrhosis, nonalcoholic fatty liver disease, and HCV cirrhosis cohorts, respectively, compared to healthy volunteers	Homo sapiens	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)